News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Verastem, Inc. (VSTM) Release: Scientific Data on PI3K/mTOR Inhibitor VS-5584 Published in Molecular Cancer Therapeutics


2/6/2013 9:31:18 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM), a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the publication of data for VS-5584 in Molecular Cancer Therapeutics. VS-5584 is a potent and selective inhibitor of the PI3K/mTOR pathway. Previous research has described a central role of this pathway in cancer stem cells. The current study details the biochemical properties and preclinical effects of this compound in multiple human tumor models.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES